Prosecution Insights
Last updated: August 06, 2026
Application No. 18/651,633

METHODS FOR PREPARING HIGH-PURITY ARABINOSE CRYSTALS

Non-Final OA §112
Filed
Apr 30, 2024
Priority
Dec 17, 2022 — CN 202211628377.2 +1 more
Examiner
LAU, JONATHAN S
Art Unit
Tech Center
Assignee
Zhejiang Huakang Pharmaceutical Co. Ltd.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
670 granted / 1047 resolved
+4.0% vs TC avg
Minimal -18% lift
Without
With
+-18.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
48 currently pending
Career history
1084
Total Applications
across all art units

Statute-Specific Performance

§101
3.2%
-36.8% vs TC avg
§103
36.4%
-3.6% vs TC avg
§102
17.7%
-22.3% vs TC avg
§112
27.3%
-12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1047 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This application is a domestic application, filed 30 April 2024; claims benefit as a CON of PCT/CN2023/096370, filed 25 May 2023; and claims benefit of foreign priority document CHINA 202211628377.2, filed 17 Dec 2022. This foreign priority document is not in English. Claims 1-9 are pending in the current application and are examined on the merits herein. Claim Objections Claim 1 is objected to because of the following informalities: claim 1 at the section starting “operation 8” ends in a period, as well as at the end of the section starting “operation 9”. MPEP 608.01(m) provides “Each claim begins with a capital letter and ends with a period. Periods may not be used elsewhere in the claims except for abbreviations.” In this case the period at the end of the section starting “operation 8” appears to be a typographical error for a semicolon, based on the claim text as a whole. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 contains the trademark/trade name “Siemens distributed control system (DCS)” (emphasis added). Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe the DCS used in the claimed method, and, accordingly, the identification/description is indefinite. Dependent claims 2-9 incorporate all limitations of claim 1, including the trademark/trade name, and are indefinite for the same reason. Allowable Subject Matter Claims 1-9 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art is CN’338 (CN 111205338 A, published 29 May 2020, provided by Applicant in IDS filed 22 May 2024) in view of CN’854 (CN 102659854 A, published 12 Sep 2012, provided by Applicant in IDS filed 22 May 2024). Citations to CN’338 are found in the included English translation. CN’338 teaches a method for recovering arabinose from arabinose mother liquor to improve the purity and recovery rate of the finished arabinose (abstract). CN’338 teaches the general method comprising step one, alkali injection; step two, primary decoloring; step three, ion exchange; step four, concentration and crystallization; step five, centrifugal separation and redissolution; and step eight: secondary centrifugation, drying and packaging (page 6), corresponding the claimed method operations 2, 4, 3, 6 and 7, 8, and 9, respectively. Citations to CN’854 are found in the included English translation. CN’854 teaches a purification method for L-arabinose (abstract). CN’854 teaches the ordinary level of skill in the pertinent art. CN’854 teaches the selection or optimization of conditions such as temperature in the steps. (page 3). It would not have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine CN’338 in view of CN’854 in a manner that arrives as the claimed invention. While CN’338 teaches a general process for the method for recovering arabinose from arabinose mother liquor to improve the purity and recovery rate of the finished arabinose, and CN’854 teaching the ordinary level of skill in the pertinent art suggests optimization of conditions such as temperature of the steps, the closest prior art does not provide sufficient guidance to select the claimed process conditions when considering the size of the pertinent genus of process steps. Therefore the claimed invention is not obvious over the combined teachings of the closest prior art. Conclusion No claim is currently in condition for allowance. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan S Lau whose telephone number is (571)270-3531. The examiner can normally be reached Monday-Friday 9a-5p Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at (571)270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JONATHAN S LAU/ Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Apr 30, 2024
Application Filed
Jul 14, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692286
CRYSTALLIZATION OF ALLULOSE UNDER REDUCED PRESSURE
3y 9m to grant Granted Jul 28, 2026
Patent 12692287
POLYMORPHIC FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR
1y 0m to grant Granted Jul 28, 2026
Patent 12685746
CYCLODEXTRIN DERIVATIVES IN THE TREATMENT OR PREVENTION OF LYSOSOMAL NEURODEGENERATIVE DISEASES
3y 3m to grant Granted Jul 21, 2026
Patent 12678403
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR NON-ALCOHOLIC FATTY LIVER CONTAINING POLYGALIN C AS ACTIVE INGREDIENT
2y 9m to grant Granted Jul 14, 2026
Patent 12673067
METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES
2y 4m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
46%
With Interview (-18.2%)
3y 0m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1047 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month